
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Teva Pharmaceutical Industries, Ltd., has been granted FDA approvalfor a generic formulation of mitoxantrone hydrochloride injection,2 mg/mL.
Teva Pharmaceutical Industries, Ltd., has been granted FDA approval for a generic formulation of mitoxantrone hydrochloride injection, 2 mg/mL. The drug is indicated for use in combination with corticosteroids as initial therapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.





